Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis
Top Cited Papers
Open Access
- 1 February 2020
- Vol. 69 (2), 224-230
- https://doi.org/10.1136/gutjnl-2019-318365
Abstract
Objective To establish the non-inferior efficacy of vonoprazan versus lansoprazole in the treatment of Asian patients with erosive oesophagitis (EO). Design In this phase III, double-blind, multicentre study, patients with endoscopically confirmed EO were randomised 1:1 to receive vonoprazan 20 mg or lansoprazole 30 mg, once daily for up to 8 weeks. The primary endpoint was EO healing rate at 8 weeks. The secondary endpoints were EO healing rates at 2 and 4 weeks. Safety endpoints included treatment-emergent adverse events (TEAEs). Results In the vonoprazan (n=238) and lansoprazole (n=230) arms, 8-week EO healing rates were 92.4% and 91.3%, respectively (difference 1.1% (95% CI -3.822% to 6.087%)). The respective 2-week EO healing rates were 75.0% and 67.8% (difference 7.2% (95% CI -1.054% to 15.371%)), and the respective 4-week EO healing rates were 85.3% and 83.5% (difference 1.8% (95% CI -4.763% to 8.395%)). In patients with baseline Los Angeles classification grade C/D, 2-week, 4-week and 8-week EO healing rates were higher with vonoprazan versus lansoprazole (2 weeks: 62.2% vs 51.5%, difference 10.6% (95% CI -5.708% to 27.002%); 4 weeks: 73.3% vs 67.2%, difference 6.2% (95% CI -8.884 to 21.223); and 8 weeks: 84.0% vs 80.6%, difference 3.4% (95% CI -9.187% to 15.993%)). Overall, EO healing rates appeared higher with vonoprazan versus lansoprazole. TEAE rates were 38.1% and 36.6% in the vonoprazan and lansoprazole group, respectively. Conclusion Our findings demonstrate the non-inferior efficacy of vonoprazan versus lansoprazole in terms of EO healing rate at 8 weeks in this population. Safety outcomes were similar in the two treatment arms.Keywords
Funding Information
- Takeda Pharmaceutical Company Ltd.
This publication has 37 references indexed in Scilit:
- Prevalence of gastroesophageal reflux disease in Korea and associated health‐care utilization: A national population‐based studyJournal of Gastroenterology and Hepatology, 2012
- Characterization of a Novel Potassium-Competitive Acid Blocker of the Gastric H,K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438)The Journal of pharmacology and experimental therapeutics, 2011
- A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glandsBiochemical Pharmacology, 2011
- A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in AnimalsThe Journal of pharmacology and experimental therapeutics, 2011
- 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related DiseasesJournal of Pharmacology and Experimental Therapeutics, 2010
- W1100 Intragastric pH Holding Time of pH <4 Predicts Low Erosive Esophagitis (EE) Healing RateGastroenterology, 2010
- Review article: the clinical pharmacology of proton pump inhibitorsAlimentary Pharmacology & Therapeutics, 2006
- Potassium-competitive acid blockade: A new therapeutic strategy in acid-related diseasesPharmacology & Therapeutics, 2005
- Pharmacological Targets in Gastro‐Oesophageal Reflux DiseaseBasic & Clinical Pharmacology & Toxicology, 2005
- Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classificationGut, 1999